Comparative Pharmacology
Head-to-head clinical analysis: DOBUTREX versus INOCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOBUTREX versus INOCOR.
DOBUTREX vs INOCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dobutamine is a direct-acting inotropic agent primarily stimulating beta-1 adrenergic receptors, with mild beta-2 and alpha-1 effects. It increases myocardial contractility and stroke volume, resulting in increased cardiac output.
Inocor (amrinone) is a phosphodiesterase III inhibitor that increases intracellular cAMP in cardiac and vascular smooth muscle, leading to positive inotropic effects and vasodilation.
2.5-20 mcg/kg/min continuous IV infusion; titrate to hemodynamic response.
Initial intravenous bolus of 0.75 mg/kg over 2-3 minutes, followed by a continuous infusion of 5-10 mcg/kg/min. Maximum dose: 10 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life approximately 2 minutes; clinical effects wane within minutes of infusion cessation due to rapid redistribution and metabolism
Terminal elimination half-life: 2.4 hours in normal renal function; prolonged in renal impairment (up to 6 hours in ESRD).
Renal: 75-80% as metabolites (3-O-methyl-dobutamine and conjugates) and unchanged drug; minor biliary/fecal elimination (<5%)
Primarily renal (80%) as unchanged drug; 20% biliary/fecal.
Category C
Category C
Inotropic Agent
Inotropic Agent